AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Jetstar to Charge for Overhead Cabin Bags From February 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
CAMBRIDGE, Mass., March 12, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on April 11, 2018 in New York City from 8:30 a.m. – 11:00 a.m. ET. Vericel executives will provide business updates and facilitate discussions with surgeon thought leaders who currently use Vericel products in their practices. Also speaking will be world champion swimmer, best-selling author, five-time Olympian and MACI® (autologous cultured chondrocytes on porcine collagen membrane) patient Dara Torres.
The presentation will be live webcast at http://investors.vcel.com/events-presentations. For those not available to listen to the live broadcast, a replay will be archived until April 10, 2019 and available at http://investors.vcel.com/events-presentations. For more information or to RSVP please contact Kelly Mueller at [email protected].
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two advanced cell therapy products in the United States. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
(vcel-corp)
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
Solebury Trout
[email protected]
+1 (646) 378-2947
Lee Stern
Solebury Trout
[email protected]
+1 (646) 378-2922
